A5090262803- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Cancer Genomics and Diagnostics
- Advanced biosensing and bioanalysis techniques
- Immunotherapy and Immune Responses
- Neuroendocrine Tumor Research Advances
- Radiopharmaceutical Chemistry and Applications
- Lymphoma Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- Virus-based gene therapy research
- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Cancer Research and Treatments
- Cancer Mechanisms and Therapy
- Chronic Myeloid Leukemia Treatments
- Virology and Viral Diseases
- Neuroblastoma Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- HER2/EGFR in Cancer Research
- Glycosylation and Glycoproteins Research
Comprehensive Cancer Center Mainfranken
2019-2025
National Center for Tumor Diseases
2024-2025
Universitätsklinikum Würzburg
2014-2025
Cancer Research Center
2023
University of Würzburg
2005-2014
Mayo Clinic in Arizona
2005
German Cancer Research Center
1977
DKFZ-ZMBH Alliance
1977
Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in phase 1 trial patients with previously treated small-cell lung cancer.In this 2 trial, we evaluated the safety of tarlatamab, administered intravenously every weeks at dose 10 mg or 100 mg, cancer. The primary end point was objective response (complete partial response), as assessed by blinded independent central review according to Response Evaluation Criteria...
PURPOSE Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb–mediated tumor lysis. Herein, we report phase I results of tarlatamab patients PATIENTS AND METHODS This study evaluated relapsed/refractory The primary end point was safety. Secondary points included antitumor activity by modified RECIST...
Abstract The evolutionary processes that underlie the marked sensitivity of small cell lung cancer (SCLC) to chemotherapy and rapid relapse are unknown 1–3 . Here we determined tumour phylogenies at diagnosis throughout immunotherapy by multiregion sequencing 160 tumours from 65 patients. Treatment-naive SCLC exhibited clonal homogeneity distinct sites, whereas first-line platinum-based led a burst in genomic intratumour heterogeneity spatial diversity. We observed branched evolution shift...
Aim: We report results of a first-in-human study pasotuxizumab, PSMA bispecific T-cell engager (BiTE R ) immune therapy mediating killing tumor cells in patients with advanced castrationresistant prostate cancer.Patients & methods: assessed once-daily subcutaneous (SC) pasotuxizumab.All SC developed antidrug antibodies; therefore, continuous intravenous (cIV) infusion was assessed.Results: A total 47 received pasotuxizumab (SC: n = 31, 0.5-172 μg/d; cIV: 16, 5-80 μg/d).The maximum tolerated...
Programmed death-ligand 1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic NSCLC clinical routine, but it has limited value distinguishing responses. Assessment of KRAS and TP53 mutations (mut) as surrogate an immunosupportive tumor microenvironment (TME) might help to close this gap.
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported . Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3, shown durable anticancer...
8510 Background: DLL3, an inhibitory Notch ligand, is a promising target as it highly expressed in SCLC compared to normal tissue. AMG 757, half-life extended BiTE immuno-oncology therapy, binds DLL3 on tumor cells and CD3 T cells, leading cell-dependent killing of tumors. Results from the first nine dosing cohorts showing preliminary efficacy 757 (confirmed partial response [PR], 14% pts) were previously presented. Here, updated safety, efficacy, pharmacokinetic data 10 ongoing phase 1...
The national Network Genomic Medicine (nNGM) Lung Cancer provides comprehensive and high-quality multiplex molecular diagnostics standardized personalized treatment recommendation for patients with advanced non-small cell lung cancer (aNSCLC) in Germany. primary aim of this study was to investigate the effectiveness nNGM precision medicine program terms overall survival (OS) using real-world data (RWD).A historical nationwide cohort analysis aNSCLC initial diagnosis between 04/2019 06/2020...
8015 Background: Brain metastases affect 40%–70% of patients with SCLC. Tarlatamab, a BiTE (bispecific T-cell engager) immunotherapy targeting delta-like ligand 3, demonstrated durable responses and promising survival outcomes in previously treated SCLC (10 mg Q2W) (DeLLphi-301; NCT05060016; Ahn M-J, N Engl J Med 2023). Here, tarlatamab efficacy safety baseline brain from DeLLphi-301 are reported. Methods: The study design has been published. Patients treated, stable, asymptomatic were...
5034 Background: mCRPC has a poor prognosis and immunotherapies are largely ineffective. PSMA is promising therapeutic target in mCRPC, pasotuxizumab x CD3 BiTE that mediates tumor cell killing. Methods: NCT01723475 was first-in-human, multicenter, dose-escalation study patients (pts) with refractory to standard therapy. Pts received as continuous intravenous infusion cohorts of 3–4 pts. Dose-escalation followed reassessment methodology design. The primary objective determine safety maximum...
Tarlatamab demonstrated a durable response and promising survival outcomes in patients with previously treated small cell lung cancer (SCLC) the phase 2, open-label DeLLphi-301 trial. Patient-reported (PROs) were evaluated to assess benefit-risk profile of tarlatamab. Patients received tarlatamab intravenously every 2 weeks at dose 10 mg (regulatory approved dose) or 100-mg until progression loss benefit. PROs, including European Organization for Research Treatment Cancer 30-item Quality...
124 Background: mCRPC has a poor prognosis and immunotherapies are largely ineffective. PSMA is promising therapeutic target in mCRPC. Pasotuxizumab x CD3 BiTE immune therapy that mediates killing of tumor cells by T cells. Methods: NCT01723475 was first-in-human, multicenter, dose-escalation study patients (pts) with refractory to standard therapy. Pts received continuous IV infusion pasotuxizumab cohorts 3–4 pts. Dose-escalation followed reassessment methodology. The primary objective...
Introduction Understanding prognosis, especially long-term outcome, in advanced nonsmall cell lung cancer (NSCLC) is crucial to inform patients, guide treatment and plan supportive palliative care. Methods Prognostic factors influencing overall survival (OS) progression-free (PFS) 2082 patients with wild-type (WT)-NSCLC (629 M1a, 249 M1b, 1204 M1c) are reported. Patients were included the prospective German CRISP registry recruiting >150 centres. Analysis for pre-therapeutic was based on...
In oncology, anti-drug antibody (ADA) development that significantly curtails response durability has not historically risen to a level of concern. The relevance and attention ascribed ADAs in oncology clinical studies have therefore been limited, the extant literature on this subject scarce. recent years, T cell engagers gained preeminence within prolific field cancer immunotherapy. These drugs whose mode action is expected potently stimulate anti-tumor immunity, may potentially induce as...
TPS8577 Background: SCLC is an aggressive neuroendocrine tumor; response to initial chemotherapy and radiotherapy often followed by recurrence, rapid progression, resistance current therapies. Delta-like ligand 3 (DLL3) inhibitory of Notch receptors that expressed in most tumors but minimally normal tissues. DLL3 may therefore be a promising target for T cell–redirecting immunotherapy. AMG 757 half-life extended BiTE antibody construct designed transiently connect DLL3-positive cells...
8582 Background: Tarlatamab, a BiTE molecule targeting DLL3 and CD3, is being studied in patients (pts) with extensive stage small cell lung cancer (ES-SCLC). 1 Up to 25% of pts diagnosed SCLC have brain metastases (BM) 50% or more will develop BM during the course disease. Pts ES-SCLC poor prognosis quality life. We analyzed characteristics outcomes included tarlatamab phase study (NCT03319940) who had baseline vs those did not. Methods: trial that progressed after ≥1 platinum-based regimen...
This is a summary of phase 2 clinical study called DeLLphi-301. The looked at how effective and safe medicine tarlatamab was in participants with small cell lung cancer (SCLC). Participants previously received least two other treatments for their SCLC. Tarlatamab new that locates protein DLL3 on the cancer, which allows T cells to attack cancer. belong body's natural defense system known as immune system. DeLLphi-301 separated into groups receive 10 mg or 100 determine dose best shrank SCLC...
TPS8603 Background: SCLC is characterized by rapid growth and early development of metastases. Platinum-based first-line chemotherapy associated with a high initial response rate; however, disease recurrence common. Delta-like ligand 3 (DLL3) Notch that upregulated aberrantly expressed on the cell surface in most SCLC, making it compelling therapeutic target. Tarlatamab an HLE BiTE immuno-oncology therapy designed to bind DLL3 target cancer cells CD3 T cells, forming cytolytic synapse...
Introduction:Patients with metastatic non-small-cell lung cancer (mNSCLC) treated immune checkpoint inhibitors (CPIs) in clinical practice may often not meet the strict inclusion criteria of trials.Our aim was to assess trial eligibility patients mNSCLC pembrolizumab monotherapy real-world and compare outcome "trialineligible" "potentially trial-eligible" patients.Methods: Data from prospective, research platform CRISP were used patient characteristics, treatment programmed cell death-ligand...
TPS9080 Background: SCLC is an aggressive neuroendocrine tumor with poor prognosis and few treatment options. Delta-like ligand 3 (DLL3) inhibitory Notch that highly expressed on the surface of most tumors but minimally in normal tissues. As such, DLL3 may be a promising therapeutic target. AMG 757 HLE BiTE immune therapy designed to redirect cytotoxic T cells cancer by binding CD3 cells, resulting cell activation expansion cell-dependent killing cells. In addition its direct antitumor...
<h3>Background</h3> Delta-like ligand 3 (DLL3) is an inhibitory Notch that highly expressed in small cell lung cancer (SCLC) and minimally normal tissues.<sup>1</sup> AMG 757, a half-life extended BiTE® immune therapy, binds to DLL3 on tumor cells CD3 T cells, resulting cell-dependent killing of cells. We report initial safety efficacy from the ongoing phase 1 study 757 patients with SCLC. <h3>Methods</h3> was administered intravenously every two weeks (with/without step dose) at doses...
3025^ Background: AFM13 is a bispecific anti-CD30, anti-CD16A antibody construct which recruits NK cells for targeted lysis of CD30+ tumor cells. HL are characterized by CD30 positivity and represent promising target AFM13. 30-40% patients (pts.) relapse after standard chemotherapy ± radiation. 2nd line therapies induce durable remission in only 50% the patients. Hence, there high medical need R/R HL. Methods: This was dose escalation trial heavily pre-treated pts. infused weekly (0.01-7.0...
Abstract Tarlatamab is a bispecific T-cell engager (BiTE ® ) immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation (CD3) molecule. In phase 2 DeLLphi-301 trial tarlatamab for patients with previously treated small cell lung cancer (SCLC), 10 mg every weeks achieved durable responses encouraging survival outcomes. Analyses updated safety data from showed that most common treatment-emergent adverse events (TEAEs) were cytokine release syndrome (CRS; 53%),...